Association Between Serum Amyloid-Beta and Renal Functions: Implications for Roles of Kidney in Amyloid-Beta Clearance

详细信息    查看全文

• 作者：Yu-Hui Liu ; Yang Xiang ; Ye-Ran Wang ; Shu-Sheng Jiao…
• 关键词：Chronic kidney disease ; Aβ ; Peripheral clearance ; Alzheimer’s disease
• 刊名：Molecular Neurobiology
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：52
• 期：1
• 页码：115-119
• 全文大小：317 KB
• 参考文献：1.Coresh J et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298(17):2038-047PubMed View Article
  2.James BD et al (2014) Contribution of Alzheimer disease to mortality in the United States. Neurology 82(12):1045-050PubMed Central PubMed View Article
  3.Lemere CA et al (2003) Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 14(1):10-8PubMed View Article
  4.Liu YH, et al (2014) Clearance of Amyloid-Beta in Alzheimer's Disease: Shifting the Action Site from Center to Periphery. Mol Neurobiol
  5.Wang YJ (2014) Alzheimer disease: Lessons from immunotherapy for Alzheimer disease. Nat Rev Neurol 10(4):188-89PubMed View Article
  6.Liu YH et al (2012) Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol 8(8):465-69PubMed
  7.Miwa K et al (2014) Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease. Neurology 82(12):1051-057PubMed View Article
  8.Li J et al (2011) Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76(17):1485-491PubMed View Article
  9.Levey AS et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604-12PubMed Central PubMed View Article
  10.Hoek FJ et al (2007) Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant 22(6):1633-638PubMed View Article
  11.Wang YJ, Zhou HD, Zhou XF (2006) Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 11(19-0):931-38PubMed View Article
  12.Ghiso J et al (1997) Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett 408(1):105-08PubMed View Article
  13.Arvanitakis Z et al (2002) Serum creatinine levels correlate with plasma amyloid Beta protein. Alzheimer Dis Assoc Disord 16(3):187-90PubMed View Article
  14.Delaney MP et al (2008) Relationship of serum cystatin C to peritoneal and renal clearance measures in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis 51(2):278-84PubMed View Article
  15.Helmer C et al (2011) Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study. Neurology 77(23):2043-051PubMed View Article
  16.Bradshaw EM et al (2013) CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci 16(7):848-50PubMed View Article
  17.Sehgal N et al (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 109(9):3510-515PubMed Central PubMed View Article
  18.Liu Y et al (2010) Circulating neprilysin clears brain amyloid. Mol Cell Neurosci 45(2):101-07PubMed Central PubMed View Article
  19.Henderson SJ et al (2014) Sustained peripheral depletion of amyloid-beta with a novel form of neprilysin does not affect central levels of amyloid-beta. Brain 137(Pt 2):553-64PubMed Central PubMed View Article
  20.Walker JR et al (2013) Enhanced proteolytic clearance of plasma Abeta by peripherally administered neprilysin does not result in reduced levels of brain Abeta in mice. J Neurosci 33(6):2457-464PubMed View Article
  
• 作者单位：Yu-Hui Liu (1)
  Yang Xiang (1)
  Ye-Ran Wang (1)
  Shu-Sheng Jiao (1)
  Qing-Hua Wang (1)
  Xian-Le Bu (1)
  Chi Zhu (1)
  Xiu-Qing Yao (1)
  Brian Giunta (2) (3)
  Jun Tan (3)
  Hua-Dong Zhou (1)
  Yan-Jiang Wang (1)
  
  1. Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital and Institute of Field Surgery, Third Military Medical University, 10 Changjiang Branch Road, Yuzhong District, Chongqing, China
  2. Neuroimmunology Laboratory, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
  3. Rashid Laboratory for Developmental Neurobiology, Silver Child Development Center, Department of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine, University of South Florida, 3515 E. Fletcher Ave., MDT 14, Tampa, FL, 33613, USA
  
• 刊物主题：Neurosciences; Neurobiology; Cell Biology; Neurology;
• 出版者：Springer US
• ISSN：1559-1182

文摘

Amyloid-beta (Aβ) plays a central role in the pathogenesis of Alzheimer’s disease (AD), and it is a major therapeutic target for AD. It is proposed that removal of Aβ in blood can facilitate Aβ clearance from the brain, representing a promising therapeutic approach for AD. However, the efficacy and mechanisms for Aβ clearance by peripheral organs and tissues remain largely unknown. In the present study, 47 chronic kidney disease (CKD) patients (16 newly diagnosed patients who had never been dialyzed and 31 patients who were receiving dialysis) and 43 normal controls (NC) were enrolled. We found that serum Aβ levels were significantly higher in CKD patients than NC. CKD patients who were receiving dialysis had lower serum Aβ levels than patients without receiving dialysis, being comparable to NC. Furthermore, serum Aβ levels were correlated with renal functions reflected by estimated glomerular filtration rate (eGFR) and residual GFR (rGFR). Our study suggests that kidney is involved in peripheral clearance of Aβ, and dialysis might be a potential therapeutic approach of Aβ removal.